Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia

Metabolism: Clinical and Experimental

Volumn 46, Issue 11, 1997, Pages 1299-1304

  Otto, Carsten ^a   Pschierer, Volkhard ^a,b   Soennichsen, Andreas C ^a   Schwandt, Peter ^a   Richter, Werner O ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Klinikum Landshut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; GEMFIBROZIL; LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD RHEOLOGY; CLINICAL ARTICLE; FAMILIAL DISEASE; FAMILIAL HYPERLIPEMIA; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 0030869793     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90234-1     Document Type: Article

References (47)

1. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, et al: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501-505, 1984
2. Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186, 1987
3. Yarnell JW, Baker IA, Sweetnam PM, et al: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 83:836-844, 1991
4. Heinrich J, Balleisen L, Schulte H, et al: Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler Thromb 14:54-59, 1994
5. Thompson SG, Kienast J, Pyke SDM, et al for the European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study Group: Haemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995
6. Razavian SM, Atger V, Giral P, et al for the PCVMETRA Group: Influence of HDL subfractions on erythrocyte aggregation in hypercholesterolemic men. Arterioscler Thromb 14:361-366, 1994
7. Koenig W, Sund M, Ernst E, et al: Association between rheology and components of lipoproteins in human blood. Results from the MONICA Project. Circulation 85:2197-2204, 1992
8. Halle M, Berg A, Keul J, et al: Association between fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 16:144-148, 1996
9. Zilversmit DB: Atherosclerosis: A postprandial phenomenon. Circulation 60:473-485, 1979
10. Weintraub MS, Grosskopf I, Rassin T, et al: Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years. Br Med J 312:935-939, 1996
11. Groot PHE, van Stiphout WAHJ, Kraus XH, et al: Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11:653-658, 1991
12. Karpe F, Steiner G, Uffelman K, et al: Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 106:83-97, 1994
13. Leschke M, Saddig C, Kleophas W, et al: Postprandial changes of blood viscosity parameters. Klin Wochenschr 68:89S-94S, 1990 (suppl)
14. Schütz E, Schuff-Werner P, Güttner Y, et al: Investigations into haemorheological significance of postprandial and fasting hypertriglyceridemia. Eur J Clin Invest 23:270-276, 1992
15. Richter WO, Jacob BG, Ritter MM, et al: Treatment of primary chylomicronemia due to familial hypertriglyceridemia by w-3 fatty acids. Metabolism 41:1100-1105, 1992
16. Bröijersen A, Eriksson M, Wiman B, et al: Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 16:511-516, 1996
17. Pazzucconi F, Mannucci L, Mussoni L, et al: Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Pharmacol 43:219-223, 1992
18. Niort G, Bulgarelli A, Cassader M, et al: Effect of short term treatment with bezafibrate on plasma fibrinogen fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenaemic patients. Atherosclerosis 71:113-119, 1988
19. Otto C, Ritter MM, Soennichsen AC, et al: Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia. Metabolism 45:1305-1311, 1996
20. Krasinski SD, Cohn JS, Schaefer EJ, et al: Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects. Evidence for delayed plasma clearance of intestinal lipoproteins. J Clin Invest 85:883-892, 1990
21. Cohn JS, Johnson EJ, Millar JS, et al: Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 34:2033-2040, 1993
22. Brunzell JD, Albers JJ, Chait A, et al: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24:147-155, 1983
23. Warnick GR, Albers JJ: A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65-76, 1978
24. Kane JP, Hardman DA, Paulus HE: Heterogeneity of apblipoprotein B: Isolation of a new species from human chylomicrons. Proc Natl Acad Sci USA 77:2465-2469, 1980
25. Schwandt P, Richter WO, Weisweiler P: Separation of apolipoprotein B subfractions by high performance gel permeation chromatography. Clin Chim Acta 157:249-252, 1986
26. Mailly F, Davignon J, Nestruck AC: Analytical isoelectric focusing with immobilized pH gradients of human apolipoprotein E from very low density lipoproteins and total plasma. J Lipid Res 31:149-155, 1990
27. Ernst E, Monshausen C, Matrai A: Blood viscosity - A comparative study on three rotational instruments. Biorheology 22:471-475, 1985
28. Matrai A, Whittington BB, Ernst E: Correction of blood viscosity to standardized hematocrit. Clin Hemorheol 5:622-625, 1985
29. Schmid-Schönbein H, Volger E, Teitel P, et al: New haemorheological techniques for the routine laboratory. Recent Adv Cardiovasc Dis 2:27S-39S, 1981 (suppl)
30. Nestel PJ: Relationship between plasma triglycerides and removal of chylomicrons. J Clin Invest 43:943-949, 1964
31. Karpe F, Steiner G, Olivecrona T, et al: Metabolism of triglyceriderich lipoproteins during alimentary lipemia. J Clin Invest 91:748-758, 1993
32. Schneeman BO, Kotite L, Todd KM, et al: Relationship between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA 90:2069-2073, 1993
33. Weintraub MS, Eisenberg S, Breslow JL: Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 79:1110-1119, 1987
34. Gnasso A, Lehner B, Haberbosch W, et al: Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. Metabolism 35:387-391, 1986
35. Simsolo RB, Ong JM, Kern PA: Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase. Metabolism 42:1486-1491, 1993
36. Dachet C, Cavallero E, Martin C, et al: Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis 113:1-9, 1995
37. Vu-Dac N, Schoonjans K, Koseykh V, et al: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750, 1995
38. Shepherd J, Packard CJ, Stewart JM, et al: Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 74:2164-2177, 1984
39. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237-1245, 1987
40. Mänttäri M, Koskinen P, Manninen V, et al: Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels. Atherosclerosis 81:11-17, 1990
41. Kahri J, Sane T, van Toi A, et al: Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridemic patients. J Intern Med 238:429-436, 1995
42. Ruhenstroth-Bauer G, Mössmer G, Ottl J, et al: Highly significant negative correlations between erythrocyte aggregation value and serum concentration of high density lipoprotein cholesterol in a sample from a normal population and in patients with coronary heart disease. Eur J Clin Invest 17:275-279, 1987
43. Dalaker K, Hjermann I, Prydz H: A novel form of factor VII in plasma from men at risk for cardiovascular disease. Br J Haematol 61:315-322, 1985
44. Cigolini M, Targher G, de Sandre G, et al: Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. Eur J Clin Invest 24:126-130, 1994
45. Schmitz-Huebner U, Thompson SG, Balleisen L, et al: Lack of association between haemostatic variables and the presence or the extent of coronary arteriosclerosis. Br Heart J 59:287-291, 1988
46. ECAT Angina Pectoris Study Group: ECAT Angina Pectoris Study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8-17, 1993
47. Betteridge DJ, Bakowski M, Taylor UG, et al: Treatment of severe diabetic hyperlipoproteinemia by plasma exchange. Lancet 1:1368, 1978 (letter)